ARQT
HOLD / NEUTRALNeutralComposite
57.80
Technical
71.50
Fundamental
48.70
Rank
—
Price
27.10
Hurst
0.52
As of
Aug 6, 2026
Daily
Arcutis Biotherapeutics, Inc.
HealthcareBiotechnologyArcutis Biotherapeutics is a biopharmaceutical company developing and commercializing medications for skin conditions. Its primary offering is ZORYVE, a topical roflumilast formulation available in cream and foam versions for treating plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and psoriasis affecting the scalp and body. The company also has ARQ-234 in development, a fusion protein designed to activate the CD200 receptor. Based in Westlake Village, California, Arcutis was founded in 2016.
Market cap
$4.0B
P/E (trailing)
145.77
P/E (forward)
23.96
PEG ratio
—
Dividend yield
0.00%
Beta
1.58
52w range
19.30 – 33.30
Return on equity
+15.86%
Profit margin
+6.15%
Revenue growth
+59.30%
Earnings growth
—
Price history
1Y: 32.07 (+26.7%) · range 19.50–32.82
Cycle position
85/ 100 cycle scoreEXIT ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 3 · NOT READY · exit proximity 45
Conviction
21/ 100 · maturity 86%
VScore.3614
Buildup.2135
EMA entry setup.273
Fundamentals.1649
Volume profile
POC
26.44
Price vs POC
+21.3%
Overhead supply
3%
Runway
open sky
Value area 23.50–28.54 · 3% of 120d volume overhead · clean runway
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| trend-signal | 0.052 | Oct 20, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -10.48% | +0.42% | mature |
| 40d | -4.81% | +5.11% | mature |